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Vagus nerve stimulation (VNS) is currently Food and Drug Administration-approved for treat-
ment of both medically refractory partial-onset seizures and severe, recurrent refractory
depression, which has failed to respond to medical interventions. Because of its ability
to regulate mechanisms well-studied in neuroscience, such as norepinephrine and sero-
tonin release, the vagus nerve may play an important role in regulating cerebral blood
flow, edema, inflammation, glutamate excitotoxicity, and neurotrophic processes. There
is strong evidence that these same processes are important in stroke pathophysiology.
We reviewed the literature for the role of VNS in improving ischemic stroke outcomes by
performing a systematic search for publications in Medline (1966–2014) with keywords
“VNS AND stroke” in subject headings and key words with no language restrictions. Of
the 73 publications retrieved, we identified 7 studies from 3 different research groups that
met our final inclusion criteria of research studies addressing the role of VNS in ischemic
stroke. Results from these studies suggest that VNS has promising efficacy in reducing
stroke volume and attenuating neurological deficits in ischemic stroke models. Given the
lack of success in Phase III trials for stroke neuroprotection, it is important to develop new
therapies targeting different neuroprotective pathways. Further studies of the possible role
of VNS, through normally physiologically active mechanisms, in ischemic stroke therapeu-
tics should be conducted in both animal models and clinical studies. In addition, recent
advent of a non-invasive, transcutaneous VNS could provide the potential for easier clinical
translation.
Keywords: stroke, middle cerebral artery occlusion, glutamate excitotoxicity, neuroinflammation, cerebral blood
flow
INTRODUCTION
HISTORY OF VAGUS NERVE STIMULATION AND ITS APPLICATION
Since the early half of the twentieth century, experiments showing
that vagus nerve stimulation (VNS)-evoked neuronal responses
helped investigators study the nucleus tractus solitarius (NTS),
the main central nervous system afferent connection of the vagus
nerve, and its projections to various cortical structures (1, 2). Ini-
tial studies on the effect of VNS on the central nervous system
in animal seizure models (dogs, cats, monkeys, rats) all demon-
strated beneficial effects of VNS in seizure suppression (3–6).
In 1988, the first reported pilot studies for treatment of med-
ically refractory seizures in four patients suggested that VNS had
potential for effective seizure control in humans as well (7). In
1997, the U.S. Food and Drug Administration (FDA) approved
the use of VNS for treatment of medically refractory partial-onset
seizures. In 2005, VNS was approved by the FDA for treatment
of severe, recurrent unipolar, and bipolar depression in patients
with a history of failed response to at least four antidepressant
interventions (8). The potential of VNS to treat partial complex
epilepsy, generalized epilepsy, involuntary movement disorders,
depression, migraine, and neuropsychiatric disorders has also been
proposed (9).
VAGUS NERVE STIMULATION: ANATOMY AND MECHANISMS
The vagus nerve, while commonly considered to be a parasympa-
thetic efferent nerve, is composed of about 80% afferent sensory
fibers carrying information from the periphery to the brain (10). In
the central nervous system, the vagus primarily projects to the NTS
and releases excitatory neurotransmitters (glutamate and aspar-
tate), inhibitory neurotransmitter (γ-aminobutyric acid), acetyl-
choline, and other neuropeptides for signal transduction (11).
Subsequently, the NTS has widespread efferent pathways in the
central nervous system to the parabrachial nucleus, reticular for-
mation, basal forebrain, amygdala, hippocampus, hypothalamus,
dorsal raphe, cerebellum, and spinal cord (12). NTS projections
to brainstem nuclei (locus coeruleus and dorsal raphe magnus)
modulate serotonin and norepinephrine (NE) release to the entire
brain (13). Despite the current level of understanding of vagus
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FIGURE 1 | Effects of vagus nerve stimulation. Vagus nerve stimulation has been shown to modulate the release of a variety of factors that regulate
important mechanisms in stroke pathophysiology, such as cerebral blood flow, neurotrophism, neurogenesis, excitotoxicity, and inflammation.
nerve anatomy, the mechanisms responsible for VNS treatment
efficacy are still poorly understood.
Acutely stimulating the vagus nerve has been shown to cause
activation and deactivation in various regions of the brain, with an
increased VNS pulse width producing proportionally more acti-
vation than deactivation when compared to a lower pulse width
(14). While the final outcome of these changes has not been
clearly established, there is experimental evidence for the role of
the vagus nerve in regulating a number of distinct physiological
pathways: cerebral blood flow (CBF), melanocortins and inflam-
mation, glutamate excitotoxicity, NE, and neurotrophic processes
(Figure 1) (15). When utilized in treatment of epilepsy, VNS
can be accomplished with a three-component apparatus: (1) a
multiprogramable bipolar pulse generator implanted subcuta-
neously in the left chest wall below the clavicle, (2) two helical
electrodes wrapped around the vagus nerve in the cervical area
and linked to the pulse generator, and (3) a programing wand
linked to software that allows for programing and assessment
(12). Individual patients respond best to different combinations
of parameter settings and it is the responsibility of the indi-
vidual physician to optimize these settings. Initial parameters
are typically set to an output current of 0.25 mA (and eventu-
ally increased to 2–3 mA as tolerated), signal frequency of 30 Hz,
pulse width of 250–500µs, stimulation “on” time 30 s, and stim-
ulation off-time 300 s (16). Traditionally, VNS treatment utilizes
the left vagus nerve due to fear for theoretically increasing risk
of cardiac side effects. Some evidence suggests that long-term
right-sided VNS is actually associated with reactive airway dis-
ease and can be considered if left-sided VNS cannot be per-
formed (17). Currently known side effects of VNS, in addition
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FIGURE 2 | Model of ischemic stroke acute pathophysiology. Detrimental acute effects of ischemic stroke can be conceptualized into two separate but
highly inter-related physiological entities, neurochemical and neuroinflammation injury, that ultimately lead to cellular damage and death. These detrimental
effects function in a positive feedback loop.
to the involvement of surgery, include cough, hoarseness, voice
alteration, and paresthesias (18).
ISCHEMIC STROKE: RELEVANCE AND PATHOPHYSIOLOGY
Stroke (cerebrovascular disease) is the fourth leading cause of
death in the United States, with approximately 795,000 peo-
ple experiencing a new or recurrent stroke every year (19).
Ischemic stroke accounts for more than 80% of stroke that
occurs in the United States. Acute neuronal damage from ischemic
stroke can be considered to be generated from two main mech-
anisms: neurochemical changes and neuroinflammatory injury
(Figure 2).
The current model for acute neurochemical changes after
ischemic stroke describes decreased perfusion and ATP deple-
tion as the cause of electrochemical gradient disruption, release
of neurotransmitters (e.g., glutamate excitotoxicity), cytotoxic
edema, oxidative stress, and cell death pathways (20). Neuroin-
flammatory injury is dependent on inflammatory cytokines and
adhesion molecules that recruit neutrophils, macrophages, and
activate microglia. The combination of neurochemical and neu-
roinflammatory injury leads to endothelial damage and failure of
the blood–brain barrier, which results in intracerebral hemorrhage
and edema (21). These deleterious events can be conceptualized as
a positive feedback loop. This study looks to further examine evi-
dence for the role of VNS in the setting of ischemic stroke in the
current literature and possible mechanisms of action to explain
the observed results.
METHODS
A systematic search was performed for publications in Medline
(1966–2014) with keywords “VNS AND stroke” in subject head-
ings and key words with no language restrictions. Of the 73
publications retrieved, we identified 7 studies from 3 different
FIGURE 3 | Study inclusion criteria methodology.
research groups that met our final inclusion criteria (Figure 3)
of research studies addressing the role of VNS in ischemic stroke.
Two reviewers, PC and AB, independently selected the relevant
studies and discrepancies about inclusion were resolved by VH.
Studies included were all experimental animal studies because
VNS remains a novel treatment idea with no clinical data to
date. An additional search of references using Highwire resulted
in two additional relevant abstracts but no available data were
provided.
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RESULTS
Our search yielded seven studies that have examined the effect of
VNS on improving outcomes, as measured by neurological deficit
score (NDS), stroke volume, forelimb strength, and a bradykinesia
assessment task after various rat ischemic stroke models (22–28).
Detailed study characteristics are listed in Table 1. Five studies
stimulated the right vagus nerve 30 min after ischemia at 5-min
intervals for a total of 60 min in rats. In these studies, the same
stimulation strength and frequencies were used but the dura-
tion varied between either 0.5 or 0.3 ms. Two additional studies
Table 1 | Detailed study characteristics and treatment.
Study Study groups Ischemia model VNS stimulation VNS duration
Ay et al. (22) Right VNS experiment gr 1
Right VNS experiment gr 2
Control gr (n=6 in each gr)
Right TMCAO (120 min) a30 min after ischemia; 0.5 ms
EG1: stimulation every 30 min
EG2: stimulation every 5 min
3 h
Summary: right VNS reduced infarct size and improved functional scores with two different stimulation protocols after TMCAO
Ay et al. (23) Right VNS experiment gr
Control gr (n=8 in each gr)
Right TMCAO (120 min – right
VNS)
a30 min after ischemia; 0.5 ms
stimulation every 5 min
1 h
Left VNS experiment gr Right TMCAO (105 min – left VNS)
Control gr (n=8 in each gr)
a30 min after ischemia; 0.5 ms
stimulation every 5 min
1 h
Summary: both right and left VNS reduced infarct size and improved functional scores
Ay and Ay (26) Right VNS experiment gr with
intact SPG
Right VNS experiment gr with
SPG ablation
Right TMCAO (120 min – right
VNS)
a30 min after ischemia; 0.5 ms
stimulation every 5 min
1 h
Summary: right VNS reduced infarct size and improved functional scores in SPG-intact and SPG-damaged animals
Hiraki et al. (24) Right VNS experiment gr (n=10)
Control gr (n=10)
Sham (n=8)
Right TMCAO (120 min) a30 min after ischemia; 0.3 ms
stimulation every 5 min
1 h
Summary: right VNS reduced infarct size and improved functional scores
Sun et al. (25) Right VNS experiment gr
Control group (n=8 in each
group)
Right TMCAO (120 min) a30 min after ischemia; 0.3 ms
stimulation every 5 min
1 h
Right VNS experiment gr
Control gr (n=8 in each group)
Right PMCAO with
photochromatic occlusion
a30 min after ischemia; 0.3 ms
stimulation every 5 min
1 h
Summary: right VNS reduced infarct size after both TMCAO and PMCAO but only improved functional scores after TMCAO and
not PMCAO
Khodaparast et al. (27) Left VNS experiment gr (n=6)
Control group (n=9)
Endothelin-1 injection at forelimb
area of primary motor cortex
b50 ms within successful pull
attempt; 0.1 ms stimulation, 15
pulses over 500 ms
25 days
Summary: left VNS paired with rehabilitative training restored forelimb strength to pre-lesion performance
Khodaparast et al. (28) Left VNS experiment gr (n=8)
Control group (n=9)
Endothelin-1 injection at forelimb
area of primary motor cortex
b50 ms within successful pull
attempt; 0.1 ms stimulation, 15
pulses over 500 ms
25 days
Summary: left VNS paired with rehabilitative training restored forelimb function to pre-lesion performance
MCAO, middle cerebral artery occlusion; VNS, vagus nerve stimulation; gr, group; TMCAO, temporary middle cerebral artery occlusion; PMCAO, permanent middle
cerebral artery occlusion; SPG, sphenopalatine ganglion.
aGroups used 0.5 mA and 20 Hz pulse trains.
bGroups used 0.8 mA and 30 Hz pulse trains.
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stimulated the right vagus nerve over a period of 25 days during
rehabilitation training. One study included a left VNS protocol
with 105 min occlusion of the right middle cerebral artery (23) and
a third group included a pdMCAO model using photochromatic
occlusion (25).
Of the studies that measured infarct volume, four performed
staining of 2 mm sections of unfixed brain tissue with 2% 2,3,5-
triphenyltetrazolium chloride (TTC) (22, 23, 25, 26). One study
used overnight fixation of 10-µm sections of brain tissue stained
with hematoxylin–eosin (HE) (24). Previous data in animal mod-
els of MCAO suggested that TTC and HE staining are significantly
correlated when quantifying ischemic injury (29, 30). Overall, a
significant decrease in infarct volume was seen in all experimental
groups given VNS as compared to control groups following induc-
tion of ischemic stroke. All studies showed significant decrease
in infarct volume in VNS treatment groups. One group also
examined the role of the sphenopalatine ganglion (SPG), and the
possible involvement of the parasympathetic vasodilator fibers to
the anterior cerebral circulation, on VNS-mediated improvements
in outcome following ischemic stroke. Both SPG-intact and SPG-
damaged animals treated with VNS demonstrated reduced infarct
volume and improved motor outcome when compared to controls
(26). Several of the studies measured neurological deficit on a 5-
point scale following observation for forelimb flexion, resistance
to lateral movement, and circling behavior 24 h after ischemia
(22, 23). One study used a 12-point scale based on sensorimotor
measurements (25). All experiments showed a statistically signif-
icant improvement in NDS of the VNS treatment groups after
ischemic stroke in comparison to the control groups. Finally, one
group found that subsequent to rat ischemic stroke in the pri-
mary motor cortex, VNS during rehabilitative training restored
forelimb strength and bradykinesia assessment task to pre-lesion
levels while rehabilitative training alone failed to restore function
to pre-lesion levels (27, 28).
DISCUSSION
In this review of experimental studies, VNS showed consistent
favorable effects on outcome in various rat ischemic stroke models.
One commonly used model was TMCAO (transient middle cere-
bral artery occlusion), which is especially relevant for translation
into clinical application because occlusion of the middle cerebral
artery is the leading worldwide cause of ischemic stroke. In com-
parison to controls, VNS-treated groups demonstrated attenuated
infarct size, reduced neurological deficit, and improved forelimb
functioning after ischemic stroke.
Current experimental evidence for the role of the vagus nerve
in regulating a number of distinct pathways involved in ischemic
stroke pathophysiology include: (A) CBF, (B) melanocortins and
inflammation, (C) glutamate excitotoxicity, (D) NE, and (E)
neurotrophic processes (15).
CEREBRAL BLOOD FLOW
Vagus nerve stimulation used in rats has been shown to decrease
CBF during 30 s stimulation periods in an ischemic stroke model
and attenuate cerebral edema after brain injury (23, 31). In
patients with treatment-refractory major depressive disorder, CBF
decreases (left and right lateral orbitofrontal cortex, left inferior
temporal lobe) and increases (right dorsal anterior cingulated, left
posterior limb of internal capsule/medial putamen, right supe-
rior temporal gyrus, left cerebellar body) were seen in different
anatomical regions after VNS (32).
MELANOCORTINS AND INFLAMMATION
The cholinergic anti-inflammatory pathway is regulated by
melanocortin-synthesizing neurons. Increased activity of this
pathway was protective while decreased activity has been associ-
ated with worse neurological symptoms in ischemic stroke patients
(33). In rats, melanocyte-stimulating hormone (NDP-α-MSH)
was shown to be neuroprotective after ischemic stroke by sup-
pressing inflammation and apoptotic cascades both centrally and
peripherally. Interestingly, bilateral vagotomy appears to blunt the
protective effects of NDP-α-MSH administration (34). Animal
models suggest that TNF levels are modulated by the cholinergic
anti-inflammatory pathway of the vagus nerve (35).
GLUTAMATE EXCITOTOXICITY
In gerbil hippocampus,VNS has been shown to decrease glutamate
release in a transient global ischemia stroke model (36). Walker and
colleagues characterized the ability for glutamate antagonists to
decrease glutamate release in the NTS in helping to block seizures
(37). VNS on patients with medically intractable epilepsy also
resulted in decreased glutamate levels (38).
NOREPINEPHRINE
Increased extracellular concentration of NE was observed in both
the hippocampus and cortex after VNS at the cervical level in rats.
Increases in NE were observed during stimulus periods and eleva-
tions returned to baseline in inter-stimulus periods. In addition,
increased intensity of VNS was associated with increasing levels of
NE concentration (39). The effects of NE release were initially
studied for its role in suppressing seizures, improving depres-
sion, enhancing learning and memory, and improving function
after traumatic brain injury. However, the convergence of differ-
ent pathophysiological mechanisms among these conditions and
ischemic stroke suggests a possibility for stroke treatment.
NEUROTROPHIC PROCESSES
Electroconvulsive therapy (ECT) and antidepressant medication
have been previously proposed to increase hippocampal brain-
derived neurotrophic factor (BDNF) and Fos protein, which pro-
motes survival and growth of neurons in patients (40). Subse-
quent research a decade later implicated VNS in upregulating gene
expression of BDNF and fibroblast growth factor (bFGF) in the
rat brain (41), suggesting a possible mechanism for the beneficial
effects seen in the treatment of depression with VNS.
We hypothesize that VNS plays a role in ischemic stroke patho-
genesis mainly through the mechanisms of attenuating excitotox-
icity and inhibiting inflammation in the acute phase and mod-
ulating neuroplasticity in the chronic phase. In the pathogenesis
of cerebral ischemia, glutamate excitotoxicity occurs in the acute
phase (minutes–hours) and inflammation begins in the subacute
phase (hours–days) (21). Excessive synaptic release of glutamate
can cause glutamate excitotoxicity, which plays a role in stroke,
nervous system trauma, epilepsy, and chronic neurodegenerative
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disorders (42). As mentioned previously, VNS was associated with
decreased glutamate release and neuroprotection in the gerbil
hippocampus (36). VNS modulates neuroinflammation by two
main mechanisms: NE release and activation of the cholinergic
anti-inflammatory pathway (33). NE has been shown to be neu-
roprotective and associated with anti-inflammation, which may
be due to its ability to suppress nitric oxide synthase, chemokines,
and cell adhesion molecules (43, 44). Reboxetine, a drug known
to inhibit reuptake of NE, has demonstrated an ability to improve
motor ability in chronic stroke patients (45), suggesting a rela-
tionship between the presence of NE and neuroprotection. VNS
also activates a cholinergic anti-inflammatory response and may
reduce both brain and systemic inflammation. Current under-
standing suggests the cholinergic anti-inflammatory pathway is
driven by the efferent vagus nerve at nAChRα7 receptors (15).
Studies demonstrate that stimulation of nAChRα7 receptors atten-
uates inflammation by regulating microglial activation in the
brain and protects neuronal cells from oxidative stress (46, 47).
Melanocortins, which function as cholinergic anti-inflammatory
pathway regulators, downregulate tumor necrosis factor-α levels
after ischemic stroke in a vagus nerve-dependent manner (34).
These studies suggest that the vagal cholinergic pathway plays an
important role in mediating inflammation after ischemic stroke.
Through all of the neuromodulatory effects of VNS, such as
release of acetylcholine, NE, and BDNF, it has been previously
proposed that VNS may induce plasticity in the motor cortex
in the chronic stage (27). However, the cellular and molecu-
lar mechanisms behind VNS-dependent neuroplasticity remain
unclear.
CNI-1493, or Semapimod, underwent Phase II clinical trials for
treatment of Crohn’s disease. This compound is known to inhibit
systemic inflammation and was shown to be protective for stroke
in preclinical testing. Subsequently, CNI-1493 was also shown to
stimulate vagal nerve activity (48). These findings further sup-
port the idea that VNS may be protective in stroke through the
suppression of inflammation.
Interestingly, a non-invasive transcutaneous VNS (T-VNS),
which stimulates the auricular branch of the vagus nerve, appeared
on the European market in 2012 for seizure frequency reduction.
T-VNS has been shown to be safe and tolerable in a retrospec-
tive and pilot study (49, 50). Initial treatment with T-VNS in one
proof of concept trial included stimulation for 1 h in the morning,
1 h at noon, and 1 h in the evening with the following settings:
stimulation frequency of 10 Hz, pulse width of 300µs, applied
voltage of about 25 V (adjusted based on individual patient tol-
erance), and stimulation area of 2 cm2 (50). These parameters
vary in different trials as different settings are being studied. This
treatment modality has also been studied in a rat seizure model,
which describes a relationship between the auricular branch of
the vagus and the autonomic and central nervous system (51).
While these studies support the possibility for T-VNS as an effec-
tive alternative, it remains to be seen whether this non-invasive
approach to VNS is equally as effective. Because traditional VNS
implantation involves surgery, its clinical application may pose
some patients’ safety problems in the setting of an acute stroke.
Hence, non-invasive VNS appears to be a more practical and
safe option. Initial studies using T-VNS in pain perception and
epilepsy suggest that there may be an association with mild ulcer-
ation of the skin at the stimulation area but no severe side
effects (52, 53).
There are several limitations with the literature we have
reviewed. First, because this is a novel topic, the literature does
not provide a universally accepted mechanism for the role of VNS
in brain ischemia and more animal work should be done to fur-
ther elucidate the mechanism. Due to this new topic in the field of
ischemic stroke research, our speculations are appropriately wide-
ranging. Also, the seven studies included in our review are derived
from three research groups, which may impose certain biases to the
results. Finally, the utility of and translation of rat stroke pathogen-
esis for human stroke outcomes is questionable because differences
in mouse genetics, anatomy, and physiology may all influence the
mechanisms associated with stroke tissue necrosis and outcomes
(54–56). For example, animal ischemic stroke models are carried
out on healthy animals whereas stroke patients often have a host
of other comorbidities (aging, hypertension, diabetes, heart dis-
ease, and medications) (57). Also, since stimulation of the vagus
nerve begins after the ischemia, it is not due to ischemic precondi-
tioning and future animal experiment methodology should strive
to better simulate clinical experience as starting therapy 30 min
from stroke onset may not be clinically translatable. Finally, our
data analysis is limited by the heterogeneity of studies, such as
surgical techniques, stroke volume data reporting, and behavioral
testing.
CONCLUSION
In experimental stroke models, VNS attenuates ischemic stroke
volume,reduces neurological deficits, and improves forelimb func-
tioning. Currently, none of 19 neuroprotection Phase III trials
analyzed were shown to have positive outcomes (58). VNS may be
a promising therapy that targets many different neuroprotective
pathways and should be studied for the treatment of post-ischemic
stroke. Past clinical experience with VNS treatment confirms its
safety and efficacy with only mild to moderate side effects that
are predictable and shown to improve over time (18). In addition,
the convenience and low morbidity of using the newly developed
T-VNS modality is encouraging for future clinical studies. Given
its efficacy in stroke models, its establishment as a safe treatment
modality for other conditions, and the convenience of new tech-
nological developments, we believe it is valid to further examine
the role of VNS as a neuromodulator in both acute and chronic
phase of clinical stroke as well as a possible secondary prophylactic
option.
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